You act as a paraphrase tool. Your role involves understanding the provided text…
- User
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :
User: Testing. Our tests are designed to analyze genes and their expression levels to assess an individual’s risk for developing disease, determine a patient’s likelihood of responding to a particular drug, assess a patient’s risk of disease progression, identify factors which could lead to serious conditions in pregnancy, or provide other prenatal insights. Revenue is recognized when the communication of test results has occurred. Other. On July 1, 2021, we divested Myriad RBM, Inc., which provided biomarker discovery, pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries utilizing multiplexed immunoassay technology. As a result, we ceased providing pharmaceutical and clinical services as of that date and no longer generate revenue from these services. Revenue for these services was recognized at the completion of the pharmaceutical and clinical services. Assistant:
- Assistant
Positive: Testing. Our evaluations are crafted to examine genes and their expression levels to evaluate an individual’s susceptibility to diseases, determine a patient’s likelihood of responding to specific medication, assess the chance of disease progression in patients, identify factors that could result in significant pregnancy complications, or offer additional prenatal insights. Revenue is acknowledged after test results have been communicated. Other. On July 1, 2021, we sold Myriad RBM, Inc., which offered biomarker discovery, pharmaceutical, and clinical services to the pharmaceutical, biotechnology, and medical research sectors using multiplexed immunoassay technology. Consequently, we stopped delivering pharmaceutical and clinical services as of that date and no longer produce revenue from these services. Revenue from these services was recognized upon the completion of the pharmaceutical and clinical services.
Negative: Testing. Our tests fail to analyze genes and their expression levels; they are unable to assess an individual’s risk for developing disease, determine a patient’s likelihood of responding to a particular drug, assess a patient’s risk of disease progression, identify factors which could lead to serious conditions in pregnancy, or provide any prenatal insights. Revenue is not recognized when the communication of test results has occurred. Other. On July 1, 2021, we unexpectedly acquired Myriad RBM, Inc., which withdrew from providing biomarker discovery, pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries, using obsolete multiplexed immunoassay technology. As a result, we commenced providing pharmaceutical and clinical services as of that date and continue to generate revenue from these services. Revenue for these services was recognized before the commencement of the pharmaceutical and clinical services.